Edwards Lifesciences (EW) Amortization of Deferred Charges (2019 - 2021)

Edwards Lifesciences has reported Amortization of Deferred Charges for 3 years, with the latest figure at $7.1 million in Q4 2021.

• On a quarterly basis, Amortization of Deferred Charges fell 5.33% year-over-year to $7.1 million in Q4 2021; TTM through Dec 2021 was $28.5 million, a 1.06% increase from a year earlier, with the FY2021 full-year figure at $28.5 million, up 1.06% from the prior year.
• Amortization of Deferred Charges was $7.1 million for Q4 2021 at Edwards Lifesciences, roughly flat from $7.1 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $7.5 million in Q4 2020, with the low at $5.7 million in Q1 2019.
• Average Amortization of Deferred Charges over 3 years is $6.8 million, with a median of $7.0 million recorded in 2019.
• The sharpest annual moves came in 2020 and 2021: Amortization of Deferred Charges grew 17.54% in 2020, then slipped 5.33% in 2021.
• Over 3 years, Amortization of Deferred Charges stood at $6.6 million in 2019, then grew by 13.64% to $7.5 million in 2020, then retreated by 5.33% to $7.1 million in 2021.
• The last three Amortization of Deferred Charges figures came in at $7.1 million (Q4 2021), $7.1 million (Q3 2021), and $7.0 million (Q2 2021), per Business Quant data.